aneuploidy
Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year
Premium
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
Natera Revenues Grow 35 Percent in Q4
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
At JPM, Natera CEO Lays Out Growth Potential for NIPT, Transplant, Cancer Testing
Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing.Â
UnitedHealthcare to Cover NIPT for Average-Risk Pregnancies
Several analysts said that the decision by UHC, the largest private payor in the US, will especially benefit Natera.
Myriad Genetics Bets Fetal DNA Enrichment Method Will Further Increase Uptake of NIPS Test
In a study involving 1,300 blood samples from pregnant women, Myriad researchers demonstrated that their method could increase the fetal fraction for almost all.
Oct 26, 2020
Yourgene H1 Revenues Up 5 Percent
May 6, 2020
Natera Q1 Revenues Grow 41 Percent
Apr 20, 2020
Yourgene Health Fiscal 2020 Revenues Up 86 Percent
Nov 8, 2019